Equities Analysts Set Expectations for TNYA FY2026 Earnings

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) – Equities researchers at HC Wainwright lifted their FY2026 earnings estimates for Tenaya Therapeutics in a research report issued on Thursday, November 5th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings of ($0.34) per share for the year, up from their prior estimate of ($0.37). The consensus estimate for Tenaya Therapeutics’ current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for Tenaya Therapeutics’ Q4 2026 earnings at ($0.08) EPS, FY2027 earnings at ($0.31) EPS and FY2028 earnings at ($0.39) EPS.

TNYA has been the subject of several other reports. Wall Street Zen raised Tenaya Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday, September 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Tenaya Therapeutics in a report on Monday, October 26th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $4.00.

Tenaya Therapeutics Trading Down 5.9%

NASDAQ TNYA opened at $0.37 on Monday. Tenaya Therapeutics has a twelve month low of $0.30 and a twelve month high of $1.56. The stock has a 50-day moving average of $0.53 and a 200 day moving average of $0.70. The stock has a market capitalization of $84.47 million, a price-to-earnings ratio of -0.76 and a beta of 2.88.

Tenaya Therapeutics (NASDAQ:TNYA) last posted its earnings results on Wednesday, November 4th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.02. The firm had revenue of $1.70 million for the quarter, compared to analysts’ expectations of $0.80 million.

Institutional Trading of Tenaya Therapeutics

Institutional investors have recently made changes to their positions in the company. R Squared Ltd increased its position in shares of Tenaya Therapeutics by 136.0% during the third quarter. R Squared Ltd now owns 74,350 shares of the company’s stock worth $45,000 after purchasing an additional 42,847 shares in the last quarter. Mirador Capital Partners LP boosted its stake in Tenaya Therapeutics by 5.8% during the 3rd quarter. Mirador Capital Partners LP now owns 957,204 shares of the company’s stock worth $578,000 after purchasing an additional 52,107 shares during the last quarter. Squarepoint Ops LLC grew its holdings in shares of Tenaya Therapeutics by 89.3% during the second quarter. Squarepoint Ops LLC now owns 659,247 shares of the company’s stock worth $487,000 after buying an additional 310,979 shares in the last quarter. Spark Investment Management LLC acquired a new stake in shares of Tenaya Therapeutics in the second quarter valued at about $26,000. Finally, Raiffeisen Bank International AG raised its position in shares of Tenaya Therapeutics by 20.0% in the second quarter. Raiffeisen Bank International AG now owns 1,200,000 shares of the company’s stock valued at $882,000 after buying an additional 200,000 shares during the last quarter. 90.54% of the stock is owned by institutional investors and hedge funds.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for genetic and other serious diseases of the heart. The company combines gene therapy, gene editing, cell therapy and small-molecule drug discovery technologies to target the underlying causes of cardiovascular disease rather than treating symptoms alone. Tenaya’s pipeline has included TN-201, an adeno-associated virus gene replacement therapy being developed for patients with MYBPC3-associated hypertrophic cardiomyopathy, and TN-401, a gene therapy candidate designed for PKP2-associated arrhythmogenic right ventricular cardiomyopathy.